Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2

The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increase...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 938556
Main Authors Long, Dan, Yu, Shujiao, Zhang, Lu, Guo, Yang, Xu, Shumin, Rao, Yuting, Huang, Zikun, Luo, Qing, Li, Junming
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 20.09.2022
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2022.938556

Cover

Loading…
Abstract The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.New onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.MethodsNew onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.The levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.ResultsThe levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.Increased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.ConclusionIncreased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.
AbstractList BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.MethodsNew onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.ResultsThe levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.ConclusionIncreased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.
The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.New onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.MethodsNew onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.The levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.ResultsThe levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.Increased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.ConclusionIncreased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.
Author Xu, Shumin
Zhang, Lu
Li, Junming
Yu, Shujiao
Huang, Zikun
Luo, Qing
Guo, Yang
Rao, Yuting
Long, Dan
AuthorAffiliation Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University , Nanchang , China
AuthorAffiliation_xml – name: Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University , Nanchang , China
Author_xml – sequence: 1
  givenname: Dan
  surname: Long
  fullname: Long, Dan
– sequence: 2
  givenname: Shujiao
  surname: Yu
  fullname: Yu, Shujiao
– sequence: 3
  givenname: Lu
  surname: Zhang
  fullname: Zhang, Lu
– sequence: 4
  givenname: Yang
  surname: Guo
  fullname: Guo, Yang
– sequence: 5
  givenname: Shumin
  surname: Xu
  fullname: Xu, Shumin
– sequence: 6
  givenname: Yuting
  surname: Rao
  fullname: Rao, Yuting
– sequence: 7
  givenname: Zikun
  surname: Huang
  fullname: Huang, Zikun
– sequence: 8
  givenname: Qing
  surname: Luo
  fullname: Luo, Qing
– sequence: 9
  givenname: Junming
  surname: Li
  fullname: Li, Junming
BookMark eNp1ks1qFTEUxwepYK19AHdZuplrvjPZCFKqXrgg1LoOmUwypmSSazJT8AV8H1_EZzJzp0IrmE2S8z_ndz44L5uzmKJtmtcI7gjp5Fvnp2nZYYjxTpKOMf6sOUec05ZgTM8evV80l6XcwXqoJISw8-bnPppsdbEDKPtDi29-_wLB6qGAOYHUlzkvZvYpguTAqoPep5BGb3QAbombpuMAbrMdgbEhFDB452y2cfb6JPsIvhyuwbH-qrGAe68rJg4-jmuWFfuqee50KPby4b5ovn64vr361B4-f9xfvT-0hlI8t6K3WCImDHS87xg1FBHhekiw4JAwaWpiIVgvISaCSEuJNohLiSmrrqYjF81-4w5J36lj9pPOP1TSXp0MKY9K59mbYJWjGCMtJeQIUd1ZDbUwVko-9I4zTivr3cY6Lv1kB1N7yzo8gT5Vov-mxnSvJCOId7gC3jwAcvq-2DKryZd1hDratBSFBSa1WQLXusXmanIqJVunjJ9P061kHxSCat0EddoEtW6C2jahRqJ_Iv8W-P-YPytQupA
CitedBy_id crossref_primary_10_1097_MD_0000000000041124
crossref_primary_10_3897_pharmacia_72_e132051
crossref_primary_10_1002_eji_202451298
crossref_primary_10_1007_s12026_024_09533_1
crossref_primary_10_5496_wjmg_v11_i3_28
crossref_primary_10_1016_j_autrev_2023_103270
crossref_primary_10_3389_fimmu_2023_1305590
crossref_primary_10_1016_j_phrs_2025_107658
Cites_doi 10.3390/molecules22010030
10.1371/journal.pone.0047748
10.4049/jimmunol.130.6.2651
10.1172/JCI110579
10.1182/blood-2011-03-340885
10.1002/art.40014
10.1056/NEJMoa1105143
10.1002/eji.200425274
10.1111/j.0300-9475.2004.01370.x
10.1056/NEJMra1100359
10.4049/jimmunol.178.4.2579
10.1038/nri3156
10.1038/nrrheum.2016.173
10.1016/j.clim.2020.108515
10.1111/j.1365-2249.2007.03464.x
10.1146/annurev.immunol.26.021607.090357
10.1073/pnas.0903158107
10.3960/jslrt.54.49
10.1038/nri1435
10.1016/j.intimp.2020.106296
10.1038/ni1263
10.1038/nm.4148
10.4049/jimmunol.135.4.2865
10.3389/fimmu.2021.648408
10.1038/s41584-018-0133-2
10.1002/art.41457
10.1111/j.1472-8206.2005.00342.x
10.1615/CritRevImmunol.2018025213
10.1038/nrrheum.2017.201
10.1016/j.jim.2014.01.008
10.1084/jem.20041982
10.1002/art.1780350606
10.1038/nrrheum.2017.70
10.1002/art.1780400928
ContentType Journal Article
Copyright Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li.
Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li
Copyright_xml – notice: Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li.
– notice: Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2022.938556
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_f4221a9906114a8ea0a7ce996dbf6564
PMC9531682
10_3389_fimmu_2022_938556
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-7be29157c0f6b854c4137fb032760359cffe775b9023739e43ac1699245c41c83
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:27:12 EDT 2025
Thu Aug 21 18:39:57 EDT 2025
Fri Jul 11 03:40:57 EDT 2025
Thu Apr 24 22:58:11 EDT 2025
Tue Jul 01 02:11:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-7be29157c0f6b854c4137fb032760359cffe775b9023739e43ac1699245c41c83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: José Carlos Crispín, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico
Reviewed by: Erwan Mortier, Centre National de la Recherche Scientifique (CNRS), France; Garth E. Ringheim, Eisai, United States
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.938556
PQID 2723157308
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_f4221a9906114a8ea0a7ce996dbf6564
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9531682
proquest_miscellaneous_2723157308
crossref_citationtrail_10_3389_fimmu_2022_938556
crossref_primary_10_3389_fimmu_2022_938556
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-20
PublicationDateYYYYMMDD 2022-09-20
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-20
  day: 20
PublicationDecade 2020
PublicationTitle Frontiers in immunology
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Crispin (B4) 2017; 37
Lotze (B30) 1985; 135
Sakai (B34) 2014; 54
Russell (B37) 2012; 7
Fontenot (B23) 2005; 6
Humrich (B11) 2010; 107
El Houda Agueznay (B36) 2007; 150
Boyman (B25) 2012; 12
Liu (B5) 2004; 59
Yang Rong (B20) 2012; 28
Hochberg (B18) 1997; 40
Alcocer-Varela (B27) 1982; 69
Comte (B31) 2017; 69
Damoiseaux (B15) 2020; 218
He (B28) 2016; 22
Graßoff (B14) 2021; 12
Sheu (B35) 2001; 61
Setoguchi (B24) 2005; 201
Nishide (B1) 2018; 14
Saadoun (B29) 2011; 365
Orozco (B32) 2020; 81
Hao (B10) 2021; 73
Malek (B7) 2008; 26
Li (B13) 2017; 13
de la Rosa (B8) 2004; 34
Gatto (B2) 2019; 15
Linker-Israeli (B26) 1983; 130
Tsokos (B3) 2011; 365
Malek (B9) 2004; 4
Valencia (B6) 2007; 178
Yang (B17) 2011; 118
Peraino (B33) 2014; 405
El-Shafey (B16) 2008; 2
Yusup (B21) 2005; 19
Bombardier (B19) 1992; 35
Humrich (B12) 2016; 12
Wu (B22) 2016; 22
References_xml – volume: 22
  year: 2016
  ident: B22
  article-title: Dysregulation of cell death and its epigenetic mechanisms in systemic lupus erythematosus
  publication-title: Molecules
  doi: 10.3390/molecules22010030
– volume: 7
  year: 2012
  ident: B37
  article-title: Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice
  publication-title: PloS One
  doi: 10.1371/journal.pone.0047748
– volume: 130
  year: 1983
  ident: B26
  article-title: Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE)
  publication-title: J Immunol
  doi: 10.4049/jimmunol.130.6.2651
– volume: 69
  year: 1982
  ident: B27
  article-title: Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus
  publication-title: J Clin Invest
  doi: 10.1172/JCI110579
– volume: 118
  year: 2011
  ident: B17
  article-title: Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular b-cell non-Hodgkin lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2011-03-340885
– volume: 69
  year: 2017
  ident: B31
  article-title: Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.40014
– volume: 365
  year: 2011
  ident: B29
  article-title: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1105143
– volume: 34
  year: 2004
  ident: B8
  article-title: Interleukin-2 is essential for CD4+CD25+ regulatory T cell function
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200425274
– volume: 59
  start-page: 198
  year: 2004
  ident: B5
  article-title: Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus
  publication-title: Scand J Immunol
  doi: 10.1111/j.0300-9475.2004.01370.x
– volume: 365
  year: 2011
  ident: B3
  article-title: Systemic lupus erythematosus
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1100359
– volume: 178
  year: 2007
  ident: B6
  article-title: Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus
  publication-title: J Immunol
  doi: 10.4049/jimmunol.178.4.2579
– volume: 12
  year: 2012
  ident: B25
  article-title: The role of interleukin-2 during homeostasis and activation of the immune system
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3156
– volume: 12
  year: 2016
  ident: B12
  article-title: Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2016.173
– volume: 218
  start-page: 108515
  year: 2020
  ident: B15
  article-title: The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2020.108515
– volume: 150
  year: 2007
  ident: B36
  article-title: Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: Prognostic value and analysis of their relationships
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.2007.03464.x
– volume: 26
  year: 2008
  ident: B7
  article-title: The biology of interleukin-2
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.26.021607.090357
– volume: 107
  year: 2010
  ident: B11
  article-title: Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus
  publication-title: Proc Natl Acad Sci U.S.A.
  doi: 10.1073/pnas.0903158107
– volume: 2
  year: 2008
  ident: B16
  article-title: Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus
  publication-title: Iran J Kidney Dis
– volume: 54
  start-page: 49
  year: 2014
  ident: B34
  article-title: The role of tumor-associated macrophages on serum soluble IL-2R levels in b-cell lymphomas
  publication-title: J Clin Exp Hematop
  doi: 10.3960/jslrt.54.49
– volume: 4
  year: 2004
  ident: B9
  article-title: Tolerance, not immunity, crucially depends on IL-2
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1435
– volume: 28
  year: 2012
  ident: B20
  article-title: Study on immune complex dissociating agent and its application in HCV antigen detection
  publication-title: J Immunol
– volume: 81
  start-page: 106296
  year: 2020
  ident: B32
  article-title: Interleukin-2 as immunotherapeutic in the autoimmune diseases
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.106296
– volume: 6
  year: 2005
  ident: B23
  article-title: A function for interleukin 2 in Foxp3-expressing regulatory T cells
  publication-title: Nat Immunol
  doi: 10.1038/ni1263
– volume: 22
  year: 2016
  ident: B28
  article-title: Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus
  publication-title: Nat Med
  doi: 10.1038/nm.4148
– volume: 135
  year: 1985
  ident: B30
  article-title: In vivo administration of purified human interleukin 2. II. half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2
  publication-title: J Immunol
  doi: 10.4049/jimmunol.135.4.2865
– volume: 12
  year: 2021
  ident: B14
  article-title: Low-dose IL-2 therapy in autoimmune and rheumatic diseases
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.648408
– volume: 15
  start-page: 30
  year: 2019
  ident: B2
  article-title: New therapeutic strategies in systemic lupus erythematosus management
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/s41584-018-0133-2
– volume: 73
  year: 2021
  ident: B10
  article-title: Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.41457
– volume: 19
  year: 2005
  ident: B21
  article-title: Cytotoxicity of abnormal savda munziq aqueous extract in human hepatoma (HepG2) cells
  publication-title: Fundam Clin Pharmacol
  doi: 10.1111/j.1472-8206.2005.00342.x
– volume: 37
  start-page: 39
  year: 2017
  ident: B4
  article-title: SLE-associated defects promote altered T cell function
  publication-title: Crit Rev Immunol
  doi: 10.1615/CritRevImmunol.2018025213
– volume: 14
  start-page: 19
  year: 2018
  ident: B1
  article-title: The role of semaphorins in immune responses and autoimmune rheumatic diseases
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2017.201
– volume: 405
  start-page: 57
  year: 2014
  ident: B33
  article-title: Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells
  publication-title: J Immunol Methods
  doi: 10.1016/j.jim.2014.01.008
– volume: 201
  year: 2005
  ident: B24
  article-title: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization
  publication-title: J Exp Med
  doi: 10.1084/jem.20041982
– volume: 35
  year: 1992
  ident: B19
  article-title: Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780350606
– volume: 61
  year: 2001
  ident: B35
  article-title: A novel role of metalloproteinase in cancer-mediated immunosuppression
  publication-title: Cancer Res
– volume: 13
  start-page: 386
  year: 2017
  ident: B13
  article-title: The rise of IL-2 therapy - a picture beyond treg cells
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2017.70
– volume: 40
  start-page: 1725
  year: 1997
  ident: B18
  article-title: Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780400928
SSID ssj0000493335
Score 2.3699608
Snippet The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been...
BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 938556
SubjectTerms IL-2
immune complex
Immunology
sIL-2R
systemic lupus erythematosus
Treg cells
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELaqSkhcKkpBXf40SJwqhWb9E8dHQK1KVXHoj9SbZTsOLGoTRLaVeAHehxfhmZixs6vNBS5cY8dO_E083ySTbxh7w70LUaHxKtwhC-lELDx6naJtPLKPxvjQpGyLT9XJlTy9Vtcbpb4oJyzLA-eFO2wl53OHe2aFzN3V0ZVOh4gsvfEtcpGkBIo-byOY-pp5rxBC5c-YGIWZw3Zxe3uH8SDnb42oFRWs3nBESa9_QjKnKZIbPuf4EdsZySK8yxe5y7Zi95g9yOUjf-yxn_hwU055bGD4eFbw89-_4AYxG2DZQ-_X0rDQt0DtkBWXCBYgf5baXNfA5ff4GegV_gCrginLDBksOrg4O4JRfnWA-4XDYdKvMDQLDfuEXR0fXX44Kca6CkWQki8L7SM3c6VD2Va-VjIgTLr1peC6IkW_gBNprbxBf66FiVK4MK8MRmoKu4ZaPGXbXd_FfQay8lq1pXZlU8ngownRudI7xY3E7WI-Y-VqkW0YRcep9sWNxeCDcLEJF0u42IzLjB2sT_mWFTf-1vk9IbfuSGLZ6QCakB1NyP7LhGbs9Qp3iw8XLbfrYn83WK6R_ircBOsZ0xODmMw4bekWX5JMt1FUFIw_-x-X-Jw9pLumRBVevmDbaEDxJbKhpX-VDP8P6JUJcQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2
URI https://www.proquest.com/docview/2723157308
https://pubmed.ncbi.nlm.nih.gov/PMC9531682
https://doaj.org/article/f4221a9906114a8ea0a7ce996dbf6564
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB6VIiQuiF-x_FRG4oSUkjj-SQ6oAtRSUOEAXWlvlu047aJtApstal-A9-FFeCZmnOyKSBUSl0iJHVuZb-yZSSbfADznzvogUXkl7pCJsHlIHFqdpK4ceh9V6XwVsy0-qcOp-DCTsy1Yl7caBNhdGdpRPanpcrF78f1yDxf8K4o40d6-rOdnZ-cY6nG-W-aFlOoaXEfDpEjJPw7e_tfeGc7zWHIzU0okqMqi_8559SgjSxUJ_Ude6DiH8i-jdHAbbg3eJHvdw38HtkJzF2709SUv78FPXP2UdB4q1r0_Svjn37_YAkHt2Kplrdtwx7K2ZtTOekomwo2RwYtttqnY8TKcMHrH37F1RZVVjymbN-zL0T4b-Fk79mNucZj4rwzNQsPeh-nB_vHbw2QovJB4Ifgq0S7wMpPap7VyhRQecdS1S3OuFVH-eZxIa-lKNPg6L4PIrUdxYygnsasv8gew3bRNeAhMKKdlnWqbVkp4F0ofrE2dlbwUuJ9kE0jXQjZ-YCWn4hgLg9EJ4WIiLoZwMT0uE3ixueVbT8nxr85vCLlNR2LTjhfa5YkZFqepBeeZRbusMDq0RbCp1T5gJFi5Gv1dMYFna9wNrj4St21Ce94ZrtE_lrhLFhPQI4UYzThuaeankce7lFQ1jD_6n-d5DDfpjDJWePoEtlFRwlN0i1ZuJ75OwOO7WbYTFf8PgIoNPQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+sIL-2R%CE%B1+leads+to+obstruction+of+IL-2+biological+function+and+Treg+cells+differentiation+in+SLE+patients+via+binding+to+IL-2&rft.jtitle=Frontiers+in+immunology&rft.au=Long%2C+Dan&rft.au=Yu%2C+Shujiao&rft.au=Zhang%2C+Lu&rft.au=Guo%2C+Yang&rft.date=2022-09-20&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.938556&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_938556
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon